VF
SYRE icon

Virtu Financial’s Spyre Therapeutics SYRE Stock Holding History

Virtu Financial’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Sell
4,351
-3,740
-46% -$273K 0.01% 629
2026
Q1 		$408K Buy
+8,091
New +$305K 0.02% 660
2024
Q3 		– Sell
-11,016
Closed -$259K – 1871
2024
Q2 		$259K Sell
11,016
-5,197
-32% -$175K 0.02% 633
2024
Q1 		$615K Buy
+16,213
New +$470K 0.05% 353
2023
Q2 		– Sell
-772
Closed -$6K – 2022
2023
Q1 		$6K Buy
+772
New +$8.47K ﹤0.01% 1386
2022
Q3 		– Sell
-1,246
Closed -$16K – 2227
2022
Q2 		$16K Buy
+1,246
New +$43.7K ﹤0.01% 1371
2021
Q1 		– Sell
-494
Closed -$97K – 2010
2020
Q4 		$97K Buy
+494
New +$102K 0.01% 1064
2017
Q4 		– Sell
-517
Closed -$64K – 2989
2017
Q3 		$64K Buy
+517
New +$48.5K ﹤0.01% 2183

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Virtu Financial's SYRE Position: Q2 2026 in Review

Virtu Financial reduced its Spyre Therapeutics (SYRE) stake by 46% in Q2 2026, selling an estimated $273K and leaving 4,351 shares worth $386K. The position accounts for 0.01% of the portfolio, ranked #629.

Virtu Financial first reported a position in SYRE in Q3 2017 and has held it in 8 quarters since. The position peaked at $615K in Q1 2024. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Virtu Financial held 4,351 shares of Spyre Therapeutics worth $386K as of Q2 2026.
  • Virtu Financial sold 3,740 Spyre Therapeutics shares in Q2 2026, an estimated $273K.
  • Spyre Therapeutics made up 0.01% of Virtu Financial's portfolio in Q2 2026, its #629 holding.
  • Virtu Financial first reported a position in Spyre Therapeutics in Q3 2017 and has held it in 8 quarters since.
  • Virtu Financial's Spyre Therapeutics position peaked at $615K in Q1 2024.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.